Trevena

Trevena Employees

8 people indexed:

Angela Bagley

Vice President, Technical Operations

6335970@w0difxd.5ui Sign up to see email

9uwqdws@68ij89q.578 Sign up to see email
Barry Shin

Executive Vice President, Chief Operating Officer and Chief Financial Officer

049uj@dzzwykl.xy4 Sign up to see email

ly8jf@jy10l0w.wk0 Sign up to see email
Carrie L. Bourdow

President and Chief Executive Officer

46.129g183@5hksh08.64p Sign up to see email

76.s961pk1@3j39i8y.gzp Sign up to see email
Joel Solomon

Vice President, General Counsel and Chief Compliance Officer

7k93wpdz@1g70fxp.gx0 Sign up to see email

bu6x34kq@p4h298y.izg Sign up to see email
Katrine Sutton

Vice President, Finance Planning & Analysis

d8pj7l2@bl0hq8q.29d Sign up to see email

5hp8p7x@i6jj071.j9y Sign up to see email
Mark A. Demitrack

Senior Vice President, Chief Medical Officer

g9.fw62p07ws@b9s67qq.puz Sign up to see email

64.8u8uuqwhb@l3bfj4w.wps Sign up to see email
Patricia Drake

Senior Vice President, Chief Commercial Officer

w2y34j@3ylgis2.9j7 Sign up to see email

zl8ix0@q83g0u3.5g7 Sign up to see email
Robert T. Yoder

Senior Vice President, Chief Business Officer & Head of Commercial Operations

fs.gh2gx@3p26xfp.g0u Sign up to see email

5h.9puuk@9s4wzf5.jjk Sign up to see email

Trevena Company Information

Trevena, located in Chesterbrook, PA, focuses on developing innovative medicines for patients with central nervous system disorders. The company has one FDA-approved product in the United States, OLINVYK (oliceridine) injection. Trevena’s pipeline includes several investigational drug candidates: TRV045, which is being developed for the treatment of diabetic neuropathic pain and epilepsy; TRV250, targeted for the acute treatment of migraine; and TRV734, focused on the maintenance treatment of opioid use disorder. In December 2023, Trevena raised $4 million through a private placement and warrant exercise.

Report inaccurate information